Clinical Trial Update: Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing oral lumbrokinase DLBS1033 with betahistine mesylate in benign paroxysmal positional vertigo has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Paroxysmal Positional Vertigo

Drugs mentioned

• Betahistine Mesylate (betahistine mesylate)
• Lumbrokinase DLBS1033 (lumbrokinase)

Snippet

Sponsor: Universitas Sebelas Maret | Conditions: Benign Paroxysmal Positional Vertigo (Disorder) | Phase 4 | Status: COMPLETED